bextra injury

Bextra® injury

On April 7, 2005 the FDA announced that it had asked Pfizer, Inc. to withdraw Bextra® (Valdecoxib) from the market "because the overall risk versus benefit profile for the drug is unfavorable."

Potential for increased risk of cardiovascular events
Gastrointestinal bleeding
Serious skin reactions, some resulting in death.

Speak to your doctor about alternatives to this drug immediately.

Bextra® is a non-steroidal anti-inflammatory drug (NSAIDs), known as a COX-2 selective agent. It's generic name is Valdecoxib and comes and 10 or 20 milligram doses. It is prescribed for inflammation and pain from arthritis or menstrual cramping. Other drugs in this class include Celebrex® and Vioxx®. Doctors switched patients from Vioxx® to Bextra® when Merck voluntarily removed it from the market due studies showing an increased risk for heart attack and stroke.

FDA INFORMATION

To read the FDA's announcement withdrawing Bextra®.
Click here to read the FDA questions and answers about strengthened warnings on Bextra® boxes.
To report any unexpected adverse or serious events associated with the use of Bextra® contact the FDA MedWatch program on the internet or at 1-800-FDA-1088

bextra site map

Autism Education Materials!